Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study

Marek Waluga

Abstract

2/2020 vol. 6

Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study

Marek Waluga ¹

Katedra i Klinika Gastroenterologii i Hepatologii, Śląski Uniwersytet Medyczny w Katowicach

Online publish date: 2020/06/09

View full text

AMA

Waluga M. Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study. Lekarz POZ. 2020;6(2):105-108.

APA

Waluga, M. (2020). Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study. Lekarz POZ, 6(2), 105-108.

Chicago

Waluga, Marek. 2020. "Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study". Lekarz POZ 6 (2): 105-108.

Harvard

Waluga, M. (2020). Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study. Lekarz POZ, 6(2), pp.105-108.

MLA

Waluga, Marek. "Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study." Lekarz POZ, vol. 6, no. 2, 2020, pp. 105-108.

Vancouver

Waluga M. Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study. Lekarz POZ. 2020;6(2):105-108.

Abstract

Efficacy and safety of high doses of ursodeoxycholic acid in patients with nonalcoholic hepatitis – commentary on the Ratziu study

Share

Indexed in

Integrated with